Ten SMEs have been selected to be funded and to participate in the EIT Health Digital Sandbox Programme. Chosen from around 30 applicants, the winners come from all over Europe and will receive funding and support that will help them in the development of relevant products and services through the involvement of, and collaboration with biobanks, sample holders and health registers in Europe.
The European Business Creation programme Digital Sandbox is lead by EIT Health Scandinavia, and has strong synergies with the Scandinavian strategic initiative Biobanks & Registers in Transition.
The selected SMEs represent solutions in biotech, medtech and digital health. Their innovations address a range of challenges, such as within infectious disease disorders, Alzheimer’s disease, AI cancer diagnostics and genomics data, breast and prostate cancer, melanoma.
The Digital Sandbox programme gives SMEs as much as €35 .000 in funding to help them leverage the possibilities of the "health data business" by developing new products and services that take advantage of biobanks, sample holders and quality registers in Europe.
The winning SME’s represent five EIT Health nodes - Scandinavia, Spain, UK, Germany and Innostars - supported by academic, business and public Partners from EIT Health.
”We are excited to see these companies identifying new biobank partners in Europe using data to create digital solutions that reduce healthcare costs and lead to more efficient working procedures for prevention, prediction, diagnosis, treatment and follow-up”, says Christos Vaitsis, in charge of EIT Health Digital Sandbox Programme.
The selected companies are:
Adama Innovations is working within infectious disease disorders using ID-MultiPath.
ADmit Therapeutics - Spain
ADmit is a a vitro diagnosis device that identifies first AD patients at MCI stage in blood, and then predict who of them will progress to Alzheimer’s dementia.
Artificial Intelligence using circulating miRNA microarray, NGS or PCR data as input for multi-cancer diagnosis and early detection diagnosis.
Antegenes - Estonia
Antegenesdevelops genetics-based solutions for individual breast cancer risk prediction and provides patients with medically certified and actionable follow-up instructions.
Biotx.ai - Germany
AI designed for biomedical data
Chundsell - Sweden
transformative tests to guide treatment decision for prostate cancer patients.
Dermtest - Estonia
Early detection toolsfor Melanoma
Elypta - Sweden
Molecular diagnostics company aiming to drastically improve cancer detection through ground-breaking science.
GLX Analytix - Denmark
GLX Analytix detects autoimmune and neurodegenerative disease and determines treatment effectiveness, personalising medical care.
Neos new born solutions - Spain
Detection of and monitoring infections in superficial body fluids by means of non-invasive white blood cell count with high-sensitive ultrasounds
For more information, contact:
Christos Vaitsis, Business Creation manager
Tel: +46 (0)70 930 83 34